A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Clinical trial NCT01776840 · COMPLETED
Trial details
- NCT number
- NCT01776840
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-05-16
- Primary completion
- 2021-06-30
- Enrollment
- 523
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.